Abstract
Allogeneic stem cell transplantation is a centrally important curative strategy in adults with acute myeloid leukaemia; however, relapse occurs in a significant proportion of patients and remains the leading cause of treatment failure. The prognosis for patients who relapse post‐transplant remains poor, and the development of new strategies with the ability to reduce disease recurrence without increasing transplant toxicity remains a priority. In this review, within the context of our understanding of disease biology and the graft‐versus‐leukaemia (GVL) effect, we will discuss established, evolving and novel approaches for increasing remission rates, decreasing measurable residual disease pretransplant, future methods to augment the GVL effect and the opportunities for post‐transplant maintenance. Future progress depends upon the development of innovative trials and networks, which will ensure the rapid assessment of emerging therapies in prospective clinical trials.
Original language | English |
---|---|
Journal | British Journal of Haematology |
Early online date | 11 Apr 2024 |
DOIs | |
Publication status | E-pub ahead of print - 11 Apr 2024 |
Bibliographical note
Funding:Research, Clinical Trial and Programme funding from CRUK, Blood Cancer UK, Cure Leukaemia, Leukaemia UK, Birmingham Health Partners and the Birmingham ECMC are gratefully acknowledged.
Keywords
- Allo‐SCT
- acute myeloid leukaemia
- relapse